JP2015120756A5 - - Google Patents

Download PDF

Info

Publication number
JP2015120756A5
JP2015120756A5 JP2015068416A JP2015068416A JP2015120756A5 JP 2015120756 A5 JP2015120756 A5 JP 2015120756A5 JP 2015068416 A JP2015068416 A JP 2015068416A JP 2015068416 A JP2015068416 A JP 2015068416A JP 2015120756 A5 JP2015120756 A5 JP 2015120756A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
layer
range
coated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015068416A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015120756A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015120756A publication Critical patent/JP2015120756A/ja
Publication of JP2015120756A5 publication Critical patent/JP2015120756A5/ja
Pending legal-status Critical Current

Links

JP2015068416A 2008-11-18 2015-03-30 2−オキソ−1−ピロリジン誘導体を含む持続放出製剤 Pending JP2015120756A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08105817 2008-11-18
EP08105817.4 2008-11-18
EP09100312.9 2009-06-02
EP09100312 2009-06-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011543763A Division JP5954890B2 (ja) 2008-11-18 2009-11-17 2−オキソ−1−ピロリジン誘導体を含む持続放出製剤

Publications (2)

Publication Number Publication Date
JP2015120756A JP2015120756A (ja) 2015-07-02
JP2015120756A5 true JP2015120756A5 (enExample) 2016-02-12

Family

ID=41381618

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011543763A Active JP5954890B2 (ja) 2008-11-18 2009-11-17 2−オキソ−1−ピロリジン誘導体を含む持続放出製剤
JP2015068416A Pending JP2015120756A (ja) 2008-11-18 2015-03-30 2−オキソ−1−ピロリジン誘導体を含む持続放出製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011543763A Active JP5954890B2 (ja) 2008-11-18 2009-11-17 2−オキソ−1−ピロリジン誘導体を含む持続放出製剤

Country Status (17)

Country Link
US (3) US10172805B2 (enExample)
EP (1) EP2358360B1 (enExample)
JP (2) JP5954890B2 (enExample)
KR (1) KR101689688B1 (enExample)
CN (2) CN102215829B (enExample)
AU (1) AU2009317280B2 (enExample)
BR (1) BRPI0921313A2 (enExample)
CA (1) CA2741041C (enExample)
DK (1) DK2358360T3 (enExample)
EA (1) EA019572B1 (enExample)
ES (1) ES2602604T3 (enExample)
HU (1) HUE032275T2 (enExample)
IL (1) IL212447A (enExample)
MX (1) MX339852B (enExample)
PL (1) PL2358360T3 (enExample)
PT (1) PT2358360T (enExample)
WO (1) WO2010057870A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2346500B1 (en) 2008-10-16 2017-05-17 The Johns Hopkins University Methods and compositions for improving cognitive function
KR101689688B1 (ko) * 2008-11-18 2016-12-26 유씨비 파마, 에스.에이. 2­옥소­1­피롤리딘 유도체를 포함하는 지연 방출형 제형
WO2011107855A2 (en) * 2010-03-04 2011-09-09 Torrent Pharmaceuticals Limited Sustained release oral liquid suspension dosage form
EP2563339A1 (en) * 2010-04-29 2013-03-06 Lupin Limited Controlled release pharmaceutical compositions of brivaracetam
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
EP3127539A1 (en) * 2015-08-03 2017-02-08 Latvian Institute Of Organic Synthesis Use of 2-(5s-methyl-2-oxo-4r-phenyl-pyrrolidin-1-yl)-acetamide in the treatment of seizures
EP3397253A1 (en) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CN111407738A (zh) * 2020-04-03 2020-07-14 江苏艾立康药业股份有限公司 一种布立西坦控释制剂及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6327424A (ja) 1986-07-17 1988-02-05 Shionogi & Co Ltd 徐放性製剤およびその製造法
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5622716A (en) 1987-02-20 1997-04-22 Farmarc Nederland B.V. Process for preparing a retard product containing diltiazem for a single daily administration
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
EP0452862B1 (en) * 1990-04-18 1995-07-19 Asahi Kasei Kogyo Kabushiki Kaisha Spherical seed cores, spherical granules and process for production thereof
JP2558396B2 (ja) * 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
JPH10182438A (ja) * 1991-03-07 1998-07-07 Takeda Chem Ind Ltd 有核散剤
DE19630035A1 (de) 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US5997905A (en) 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US8168170B2 (en) * 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
ZA200505180B (en) 2002-11-28 2006-10-25 Themis Lab Private Ltd Process for manufacturing sustained release microbeads containing venlafaxine HCI
DE10353186A1 (de) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
SI21637A (sl) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
WO2006088864A1 (en) 2005-02-16 2006-08-24 Elan Pharma International Limited Controlled release compositions comprising levetiracetam
CA2600282A1 (en) * 2005-03-29 2006-10-05 Roehm Gmbh Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
WO2006125074A1 (en) * 2005-05-17 2006-11-23 Brown University Research Foundation Drug delivery formulations for targeted delivery
US20070264346A1 (en) * 2006-02-16 2007-11-15 Flamel Technologies Multimicroparticulate pharmaceutical forms for oral administration
FR2897267A1 (fr) 2006-02-16 2007-08-17 Flamel Technologies Sa Formes pharmaceutiques multimicroparticulaires pour administration per os
EP2041084B1 (en) 2006-06-08 2013-11-06 UCB Pharma, S.A. Co-crystals of pyrrolidinones
DE102006035549A1 (de) * 2006-07-27 2008-01-31 Evonik Röhm Gmbh Arzneiform mit mindestens zweischichtiger Trennschicht
NZ575171A (en) * 2006-08-31 2012-04-27 Aptalis Pharmatech Inc Drug delivery systems comprising solid solutions of weakly basic drugs
CN101801356B (zh) * 2007-09-21 2016-10-19 赢创罗姆有限公司 耐受乙醇影响的非阿片类的pH依赖性受控释放的药物组合物
WO2009102964A2 (en) * 2008-02-14 2009-08-20 Nordson Corporation Apparatus for testing containers, tray for holding cylinders and suction-basedchuck for robotic arm
KR101788804B1 (ko) * 2008-11-18 2017-10-20 유씨비 파마, 에스.에이. 2―옥소―1―피롤리딘 유도체를 포함하는 연장 방출 제형
KR101689688B1 (ko) * 2008-11-18 2016-12-26 유씨비 파마, 에스.에이. 2­옥소­1­피롤리딘 유도체를 포함하는 지연 방출형 제형

Similar Documents

Publication Publication Date Title
JP2015143256A5 (enExample)
Lecomte et al. Polymer blends used for the aqueous coating of solid dosage forms: importance of the type of plasticizer
Siepmann et al. Polymer blends for controlled release coatings
Wu et al. Non-traditional plasticization of polymeric films
CN1404389B (zh) 时控脉冲给药系统
HRP20171506T1 (hr) Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka
Gaber et al. Mini-tablets versus pellets as promising multiparticulate modified release delivery systems for highly soluble drugs
JP2005514386A5 (enExample)
AR017747A1 (es) Perlas farmaceuticas con recubrimiento entcrico, opcionalmente recubiertas con un anti-adherente dispuesto en el exterior de dicho recubrimiento entcrico, y un procedimiento para preparar dichas perlas farmaccuticas con recubrimiento entcrico
HRP20150123T1 (hr) Plutajući farmaceutski oblici kontroliranog oslobađanja
HRP20171458T1 (hr) Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka
JP2012515163A5 (enExample)
SK106295A3 (en) Thermoplastic for drug covers production, manufacturing process and use thereof
JP2015205922A5 (enExample)
RU2015110824A (ru) Фармацевтическая или нутрицевтическая композиция с замедленным высвобождением и стойкостью к воздействию этанола
JP2009525300A5 (enExample)
RU2014101227A (ru) Композиция покрытия, подходящая для фармацевтических или нутрицевтических лекарственных форм
BR112013028453B1 (pt) Uso de uma composição de revestimento, formas de dosagem farmacêuticas ou nutracêuticas gastrorresistentes, e composição do polímero do núcleo/invólucro
WO2011045769A3 (fr) Forme pharmaceutique orale solide anti-mésusage et dotée d'un profil spécifique de libération modifiée
JP2013502993A5 (enExample)
Albanez et al. Enteric coating process of diclofenac sodium pellets in a fluid bed coater with a wurster insert: Influence of process variables on coating performance and release profile
Tan et al. Investigation for the quality factors on the tablets containing medicated pellets
JP2018521030A5 (enExample)
JP2008507483A (ja) 安定な作用物質放出プロフィールを有するコーティングされた剤形の製造方法
CA2478407A1 (en) Polyvinyl acetate film coatings with controlled release and high stability